RGD Reference Report - Prolactin promotes hepatocellular carcinoma through Janus kinase 2. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Prolactin promotes hepatocellular carcinoma through Janus kinase 2.

Authors: Yeh, Yao-Tsung  Lee, King-Teh  Tsai, Chia-Jung  Chen, Yu-Jie  Wang, Shen-Nien 
Citation: Yeh YT, etal., World J Surg. 2012 May;36(5):1128-35. doi: 10.1007/s00268-012-1505-4.
RGD ID: 125097525
Pubmed: PMID:22392353   (View Abstract at PubMed)
DOI: DOI:10.1007/s00268-012-1505-4   (Journal Full-text)


BACKGROUND: Hepatocellular carcinoma (HCC) is one human cancer with obvious gender disparity. This study investigated the association of aberrant prolactin levels with HCC risk and the potential impacts on HCC of the prolactin receptor (PRLR)/Janus kinase 2 (JAK2) signaling.
METHODS: Serum prolactin of 63 HCC patients and 162 subjects without HCC was measured by radioimmunoassay. The expressions of PRLR and phosphorylated JAK2 (p-JAK2) in 82 retrospectively collected HCC specimens were evaluated by immunohistochemistry and further incorporated into the survival analysis. The immunoblotting and proliferation assays were used to analyze the effects of PRLR/JAK2 signaling on liver cancer cells with prolactin treatment.
RESULTS: Serum prolactin level was significantly higher in HCC patients than in controls. Hepatocellular carcinoma patients with high p-JAK2 expression had a significantly higher postoperative risk than those with low p-JAK2 expression. Moreover, results from the multivariate analysis indicated the prognostic role of p-JAK2 expression with respect to overall survival in HCC patients. In addition, the Kaplan-Meier survival curve showed that high p-JAK2 expression was associated with poor survival in HCC patients with high PRLR expression. The immunoblotting assay showed that prolactin induced the expression of both p-JAK2 and cyclin D1 in Hep-G2 cells. Importantly, the proliferative effects induced by prolactin could be effectively attenuated by adding AG490, a JAK2 inhibitor.
CONCLUSIONS: Increased circulating prolactin was found in HCC patients and high p-JAK2 expression could predict poor overall survival in those patients expressing high PRLR. In addition, prolactin contributed to the proliferation of liver cancer cells through PRLR/JAK2 signaling.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
AFPHumanhepatocellular carcinoma  IEP protein:increased expression:serum (human)RGD 
ALBHumanhepatocellular carcinoma  IEP protein:decreased expression:serum (human)RGD 
AfpRathepatocellular carcinoma  ISOAFP (Homo sapiens)protein:increased expression:serum (human)RGD 
AfpMousehepatocellular carcinoma  ISOAFP (Homo sapiens)protein:increased expression:serum (human)RGD 
AlbRathepatocellular carcinoma  ISOALB (Homo sapiens)protein:decreased expression:serum (human)RGD 
AlbMousehepatocellular carcinoma  ISOALB (Homo sapiens)protein:decreased expression:serum (human)RGD 
JAK2Humanhepatocellular carcinoma exacerbatesIEP protein:increased phosphorylation:liver (human)RGD 
Jak2Rathepatocellular carcinoma exacerbatesISOJAK2 (Homo sapiens)protein:increased phosphorylation:liver (human)RGD 
Jak2Mousehepatocellular carcinoma exacerbatesISOJAK2 (Homo sapiens)protein:increased phosphorylation:liver (human)RGD 
PRLHumanhepatocellular carcinoma onsetIEP protein:increased expression:serum (human)RGD 
PrlRathepatocellular carcinoma onsetISOPRL (Homo sapiens)protein:increased expression:serum (human)RGD 
PrlMousehepatocellular carcinoma onsetISOPRL (Homo sapiens)protein:increased expression:serum (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Afp  (alpha-fetoprotein)
Alb  (albumin)
Jak2  (Janus kinase 2)
Prl  (prolactin)

Genes (Mus musculus)
Afp  (alpha fetoprotein)
Alb  (albumin)
Jak2  (Janus kinase 2)
Prl  (prolactin)

Genes (Homo sapiens)
AFP  (alpha fetoprotein)
ALB  (albumin)
JAK2  (Janus kinase 2)
PRL  (prolactin)


Additional Information